A Phase 1, Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of ANG-3070 in Healthy Adult Participants
Latest Information Update: 04 Apr 2022
At a glance
- Drugs ANG 3070 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Angion Biomedica
Most Recent Events
- 30 Mar 2022 According to an Angion Biomedica media release, data from this healthy volunteer study were presented at the Virtual R&D Day on September 20, 2021.
- 03 Aug 2021 Results published in the Angion Biomedica media releaseMedia Release.
- 19 Jul 2021 Status changed from recruiting to completed.